FDA suggested that AstraZeneca Nirsevimab be used to prevent infant RSV from landing in the United States this fall.

British pharmaceutical giant AstraZeneca announced Friday that the Antibacterial Advisory Committee (AMDAC) of the US Food and Drug Administration (FDA) has unanimously recommended that AstraZeneca Nirsevimab be used to prevent respiratory syncytial virus (RSV) or RSV lower respiratory disease (LRTD) in infants. RSV is a highly contagious virus that can cause serious respiratory diseases.